- Home
- RCS vs MDAIW Comparison
RCS vs MDAIW Comparison
Compare RCS & MDAIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RCS | MDAIW |
|---|---|---|
| Founded | 1994 | N/A |
| Country | United States | United States |
| Employees | N/A | 78 |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.9M | N/A |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RCS | MDAIW |
|---|---|---|
| Price | $6.73 | $0.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 141.1K | 35.6K |
| Earning Date | 01-01-0001 | 02-27-2025 |
| Dividend Yield | ★ 10.12% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,264,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 44.52 |
| 52 Week Low | $4.51 | $0.08 |
| 52 Week High | $6.31 | $0.90 |
Technical Indicators
Market Signals| Indicator | RCS | MDAIW |
|---|---|---|
| Relative Strength Index (RSI) | 44.31 | 48.02 |
| Support Level | $6.54 | $0.45 |
| Resistance Level | $7.04 | $0.60 |
| Average True Range (ATR) | 0.14 | 0.07 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 39.33 | 59.21 |
Price Performance
Historical ComparisonAbout RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.
About MDAIW Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.